Serono changes tack

Article Abstract:

Serono of Geneva, a leader in the multiple sclerosis market has recruited the Goldman Sachs bank to explore various strategic alternatives as a necessary move before the value of its core cash-generating business centered around its multiple sclerosis franchise starts to erode. Novartis and Roche, New York-based Pfizer, Johnson &Johnson of New Jersey and London-based GlaxoSmithKline are identified as likely bidders for the company which exited 2005 with around $600 million and holds treasury shares valued at around $650 million.

Investment Banking and Securities Dealing, Investment Banking, Switzerland, Contracts & orders received, Pharmaceutical preparations, Security brokers and dealers, Contracts & orders let, Pharmaceutical industry, Investment banks, Contracts, Contract agreement, The Goldman Sachs Group Inc., Serono AG

---

Antibiotics au naturel

Article Abstract:

Lack of funding into research and economic slowdown has resulted in research in genomics for antibiotic discovery being stalled. However, an exploration of untapped sources like biodiverse resources in the world could guide in a second golden age on antibiotic discovery.

Science & research, Research, Antibiotics, Research grants, Research funding

---

Similar abstracts:

• Abstracts: Celestial Seasonings Teahouse Chai Teas. Pacific Chai Latte Mix
• Abstracts: William Haseltine. Monsanto branches out into fruits and vegetables. Mexico launches bold genome project
• Abstracts: Power to the people. A fare job. Retail therapy
• Abstracts: IASB must take a reality check. Size matters
• Abstracts: Budgetary practices and accountability habitus: a grounded theory. Accounting and NPM in UK Local Government Contributions Towards Governance and Accountability

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.